For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of
all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization …

Background Aromatase inhibitors are associated with consistent improvements in disease-
free survival but not in overall survival. We conducted a literature-based meta-analysis of …

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment
with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout …

Background In laboratory animals, the consumption of soy protein, rather than animal
protein, decreases serum cholesterol concentrations, but studies in humans have been …

BACKGROUND: There have been many randomised trials of adjuvant tamoxifen among
women with early breast cancer, and an updated overview of their results is presented …

Selective estrogen receptor modulators (SERMs) are structurally different compounds that
interact with intracellular estrogen receptors in target organs as estrogen receptor agonists …

ContextRaloxifene hydrochloride is a selective estrogen receptor modulator that has
antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid …

The selective estrogen-receptor modulators, or SERMs, chemically diverse nonsteroid
compounds, have tertiary structures that permit binding to the estrogen receptor. These …

Women with primary invasive breast cancer receive both local and systemic treatment.
Surgery and radiation therapy are local treatments given to reduce the risk of recurrent …

Background A number of randomized controlled trials (RCTs) have reported improvement in
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …